Эффективность и безопасность различных доз гимекромона у больных, перенесших холецистэктомию

Abstract

Laparoscopic cholecystectomy is the leading method of treatment of cholelithiasis. Often, postcholecystectomy syndrome develops after cholecystectomy. In most cases, its manifestations are of a functional nature and are associated with dysfunction of the Oddi sphincter. A study of the effectiveness of the drug Odeston (hymecromone) at doses of 600 mg and 1200 mg per day in patients with postcholecystectomy syndrome was conducted. 36 patients were randomized into two groups: the first group consisted of 18 patients receiving the drug hymecromone at a dosage of 600 mg per day (200 mg three times a day), the second group of 18 patients receiving the drug hymecromone 1200 mg per day (400 mg three times a day). The duration of therapy was 21 days. When assessing the pain syndrome on a visual analog scale, statistically significant dynamics (Chi2; p < 0.01) was observed in both groups after therapy, most pronounced in the second group. In the second group, normalization of the stool was noted (Chi2; p = 0.015) and a decrease in the diameter of the common bile duct (Wilcoxon criterion; p = 0.05). When assessing the dynamics of abdominal pain and its impact on daily activities 90 days after therapy, a statistically significant advantage was revealed in the second group (Chi2; p = 0.014). The data obtained indicate that Odeston is more effective in postcholecystectomy syndrome at a dose of 1200 mg per day.